Risk of febrile neutropenia in very elderly patients aged ≥80 years receiving their first cycle of R‐CHOP regimen: a nationwide real‐world study in Japan-Reference-Cited by-同舟云学术

Risk of febrile neutropenia in very elderly patients aged ≥80 years receiving their first cycle of R‐CHOP regimen: a nationwide real‐world study in Japan

Published:2022-01-03 Issue:3 Volume:197 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Matsuda Kensuke¹^ORCID,Jo Taisuke²,Shimura Arika¹,Honda Akira¹,Taoka Kazuki¹,Masamoto Yosuke¹,Matsui Hiroki³,Fushimi Kiyohide⁴,Yasunaga Hideo³,Kurokawa Mineo¹⁵^ORCID

Affiliation:

1. Department of Haematology and Oncology Graduate School of Medicine Tokyo Japan

2. Department of Health Services Research Graduate School of Medicine Tokyo Japan

3. Department of Clinical Epidemiology and Health Economics School of Public Health Tokyo Japan

4. Department of Health Policy and Informatics Tokyo Medical and Dental University Graduate School of Medicine Tokyo Japan

5. Department of Cell Therapy and Transplantation Medicine The University of Tokyo Hospital Tokyo Japan

Funder

Ministry of Health, Labour and Welfare

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18028

Reference17 articles.

1. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

2. Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices

3. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials

4. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

5. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours